Modulation of hu/mu severe combined immunodeficient (SCID) mouse arthritis by local application of human recombinant IL-1β, IL-2 and IL-6

Por KUHN, H, ERMANN, J, SACK, U
Publicado em 1997

Antimuscarinic action of quinidine on the heart? A study in myocardial preparations from cat hearts.

Por Nawrath, H., Sack, U., Zong, X.
Publicado em 1984

Immunomodulation of AT III in septic disease

Por Leonhardt, U, Lehmann, I, Sack, U, Engelmann , L
Publicado em 1999

Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis.

Por Horneff, G, Sack, U, Kalden, J R, Emmrich, F, Burmester, G R
Publicado em 1993

Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis

Por Lange, F, Bajtner, E, Rintisch, C, Nandakumar, K, Sack, U, Holmdahl, R
Publicado em 2005

Three-Dimensional Scaffold-Free Fusion Culture: the Way to Enhanced Chondrogenesis of in vitro Propagated Human Articular Chondrocytes

Por Lehmann, M., Martin, F., Mannigel, K., Kaltschmidt, K., Sack, U., Anderer, U.
Publicado em 2013

Induction of a rapid progessive cartilage destruction in SCID mice by intraarticular application of a murine fibroblast like cell line

Por Sack, U, Hirth, A, Funke, B, Wiedemeyer, K, Konrad, S, Lehmann, J, Emmrich, F
Publicado em 2001

Novel metabolites in phenanthrene and pyrene transformation by Aspergillus niger.

Por Sack, U, Heinze, T M, Deck, J, Cerniglia, C E, Cazau, M C, Fritsche, W
Publicado em 1997

Immunomodulation by mercuric chloride in vitro: application of different cell activation pathways

Por Hemdan, N Y A, Lehmann, I, Wichmann, G, Lehmann, J, Emmrich, F, Sack, U
Publicado em 2007

Comparison of phenanthrene and pyrene degradation by different wood-decaying fungi.

Por Sack, U, Heinze, T M, Deck, J, Cerniglia, C E, Martens, R, Zadrazil, F, Fritsche, W
Publicado em 1997

Immunological evaluation of the new stable ultrasound contrast agent LK565: a phase one clinical trial

Por Funke, B, Maerz, HK, Okorokow, S, Polata, S, Lehmann, I, Sack, U, Wild, P, Geisler, T, Zotz, RJ
Publicado em 2004

Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Por Rasche, F. M., Keller, F., Rasche, W. G., Schiekofer, S., Boldt, A., Sack, U., Fahnert, J.
Publicado no Clin Exp Immunol (2016)

Anti-inflammatory effects of systemic anti-tumour necrosis factor α treatment in human/murine SCID arthritis

Por Schadlich, H., Ermann, J., Biskop, M., Falk, W., Sperling, F., Jungel, A., Lehmann, J., Emmrich, F., Sack, U.
Publicado em 1999

Gene therapy of destructive arthritis in SCID mice

Por Sack, U, Hirth, A, Moessner, A, Grapenthin, M, Kahlenberg, F, Lehmann, J, Anderegg, U, Ueberla, K, Emmrich, F
Publicado em 2003

Reduction of cartilage destruction in a rapid progressive arthritis model in SCID mice

Por Sack, U, Hirth, A, Funke, B, Wiedeneyer, K, Kahlenberg, F, Anderegg, U, Krahnert, F, Lehmann, J, Emmrich, F
Publicado em 2002

MALDI MS imaging as a powerful tool for investigating synovial tissue

Por Kriegsmann, M, Seeley, EH, Schwarting, A, Kriegsmann, J, Otto, M, Thabe, H, Dierkes, B, Biehl, C, Sack, U, Wellmann, A, Kahaly, GJ, Schwamborn, K, Caprioli, RM
Publicado em 2012